•  
  •  
 

Turkish Journal of Medical Sciences

Abstract

Background/aim: No reliable, easily measurable biomarker currently exists for the screening or prognosis of lung cancer. The present study evaluates the potential utility of vascular endothelial growth factor (VEGF) and endocan, which can be readily measured in blood samples, as biomarkers for screening and prognostic assessment in lung cancer.

Materials and methods: Included in the study were 38 patients with early-stage non-small cell lung cancer (NSCLC) and 29 controls. All patients underwent surgical intervention and were monitored for 1 month postoperatively. Serum VEGF and endocan levels were measured preoperatively and postoperatively. Clinical characteristics, laboratory data, and histopathological findings were recorded for all participants.

Results: The preoperative VEGF levels of the patients were significantly higher than those of the controls (p = 0.001), while postoperative VEGF levels decreased significantly following surgery (p < 0.001). The endocan levels of the patients and controls were similar preoperatively. Additionally, endocan levels were significantly increased after the surgery in the patient group (p < 0.001). A comparison of VEGF and endocan levels according to TNM staging and tumor histopathology revealed no significant differences.

Conclusion: VEGF can serve as a potential biomarker for screening and prognostic assessment in early-stage NSCLC. In contrast, endocan did not demonstrate utility for such clinical purposes. VEGF may also be considered for the evaluation of treatment efficacy following surgical intervention.

Author ORCID Identifier

MESUT ÖZERCAN: 0000-0001-9476-9328

BURCU ANCIN: 0000-0001-7582-5486

YİĞİT YILMAZ: 0000-0001-6502-9072

AHMET MÜDERRİSOĞLU: 0000-0003-2954-360X

SERKAN UYSAL: 0000-0002-1152-2854

ULAŞ KUMBASAR: 0000-0003-0616-1326

ZEYNEP SARIBAŞ: 0000-0002-2467-9914

ERKAN DİKMEN: 0000-0002-0866-5221

RIZA DOĞAN: 0000-0003-4845-3044

DOI

10.55730/1300-0144.6100

Keywords

Endocan, Non-Small Cell Lung Cancer, Prognosis, Screening, VEGF

First Page

1424

Last Page

1434

Publisher

The Scientific and Technological Research Council of Türkiye (TÜBİTAK)

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS